Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer

PURPOSE: Multiple treatment options exist for patients with metastatic breast cancer (MBC). However, limited information is available on the impact of prior treatment duration and class on survival outcome for novel therapies, such as cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Franks, Jeffrey, Caston, Nicole E., Elkhanany, Ahmed, Gerke, Travis, Azuero, Andres, Rocque, Gabrielle B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883320/
https://www.ncbi.nlm.nih.gov/pubmed/36539670
http://dx.doi.org/10.1007/s10549-022-06823-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883320/
https://www.ncbi.nlm.nih.gov/pubmed/36539670
http://dx.doi.org/10.1007/s10549-022-06823-w

Ejemplares similares